Skip to main content
Erschienen in: Clinical Autonomic Research 1/2024

29.01.2024 | Letter to the Editor

Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction

verfasst von: Takuro Washio, Sarah L. Hissen, Ryosuke Takeda, John D. Akins, Denis J. Wakeham, Tiffany Brazile, Christopher M. Hearon Jr, James P. MacNamara, Satyam Sarma, Benjamin D. Levine, Paul J. Fadel, Qi Fu

Erschienen in: Clinical Autonomic Research | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) continues its yearly increase in the USA and now surpasses that of HF with reduced ejection fraction (HFrEF) [9]. HFpEF is associated with high morbidity, mortality, and economic cost. Medications established as part of guideline-directed medical therapy have reduced hospitalization rates and cardiovascular morbidity and mortality for patients with HFrEF [9]. However, most current drug therapies remain unsuccessful in improving clinical outcomes in patients with HFpEF. Therefore, other pharmacotherapies are urgently needed to effectively treat HFpEF. …
Literatur
1.
Zurück zum Zitat Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461CrossRefPubMed Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461CrossRefPubMed
2.
Zurück zum Zitat Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, Negrao CE (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135:302–307CrossRefPubMed Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, Negrao CE (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135:302–307CrossRefPubMed
3.
Zurück zum Zitat Belli M, Barone L, Bellia A, Sergi D, Lecis D, Prandi FR, Milite M, Galluccio C, Muscoli S, Romeo F, Barilla F (2022) Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients? Int J Mol Sci 23:14598CrossRefPubMedPubMedCentral Belli M, Barone L, Bellia A, Sergi D, Lecis D, Prandi FR, Milite M, Galluccio C, Muscoli S, Romeo F, Barilla F (2022) Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients? Int J Mol Sci 23:14598CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Bruno RM, Daghini E, Ghiadoni L, Sudano I, Rugani I, Varanini M, Passino C, Emdin M, Taddei S (2012) Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr 96:302–308CrossRefPubMed Bruno RM, Daghini E, Ghiadoni L, Sudano I, Rugani I, Varanini M, Passino C, Emdin M, Taddei S (2012) Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr 96:302–308CrossRefPubMed
5.
Zurück zum Zitat Diaz HS, Toledo C, Andrade DC, Marcus NJ, Del Rio R (2020) Neuroinflammation in heart failure: new insights for an old disease. J Physiol 598:33–59CrossRefPubMed Diaz HS, Toledo C, Andrade DC, Marcus NJ, Del Rio R (2020) Neuroinflammation in heart failure: new insights for an old disease. J Physiol 598:33–59CrossRefPubMed
6.
Zurück zum Zitat Dong M, Wen S, Zhou L (2022) The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab Syndr Obes 15:2583–2597CrossRefPubMedPubMedCentral Dong M, Wen S, Zhou L (2022) The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab Syndr Obes 15:2583–2597CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Fonkoue IT, Le NA, Kankam ML, DaCosta D, Jones TN, Marvar PJ, Park J (2019) Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure. Physiol Rep 7:e14057CrossRefPubMedPubMedCentral Fonkoue IT, Le NA, Kankam ML, DaCosta D, Jones TN, Marvar PJ, Park J (2019) Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure. Physiol Rep 7:e14057CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Hamaoka T, Murai H, Hirai T, Sugimoto H, Mukai Y, Inoue O, Takashima S, Kato T, Takata S, Usui S, Sakata K, Kawashiri MA, Takamura M (2021) Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure. J Am Heart Assoc 10:e022637CrossRefPubMedPubMedCentral Hamaoka T, Murai H, Hirai T, Sugimoto H, Mukai Y, Inoue O, Takashima S, Kato T, Takata S, Usui S, Sakata K, Kawashiri MA, Takamura M (2021) Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure. J Am Heart Assoc 10:e022637CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:e263–e421CrossRefPubMed Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:e263–e421CrossRefPubMed
10.
Zurück zum Zitat Heusser K, Tank J, Diedrich A, Fischer A, Heise T, Jordan J (2023) Randomized trial comparing SGLT2 inhibition and hydrochlorothiazide on sympathetic traffic in type 2 diabetes. Kidney Int Rep 8:2254–2264CrossRefPubMedPubMedCentral Heusser K, Tank J, Diedrich A, Fischer A, Heise T, Jordan J (2023) Randomized trial comparing SGLT2 inhibition and hydrochlorothiazide on sympathetic traffic in type 2 diabetes. Kidney Int Rep 8:2254–2264CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lambert GW, Schlaich MP, Eikelis N, Lambert EA (2019) Sympathetic activity in obesity: a brief review of methods and supportive data. Ann N Y Acad Sci 1454:56–67ADSCrossRefPubMed Lambert GW, Schlaich MP, Eikelis N, Lambert EA (2019) Sympathetic activity in obesity: a brief review of methods and supportive data. Ann N Y Acad Sci 1454:56–67ADSCrossRefPubMed
12.
Zurück zum Zitat Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, Rysevaite-Kyguoliene K, Ast J, Broichhagen J, Hodson DJ, Salgado HC, Pauza DH, Japundzic-Zigon N, Paton JFR, Murphy D (2022) GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res 130:694–707CrossRefPubMedPubMedCentral Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, Rysevaite-Kyguoliene K, Ast J, Broichhagen J, Hodson DJ, Salgado HC, Pauza DH, Japundzic-Zigon N, Paton JFR, Murphy D (2022) GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res 130:694–707CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Sarma S, MacNamara JP, Balmain BN, Hearon CM Jr, Wakeham DJ, Tomlinson AR, Hynan LS, Babb TG, Levine BD (2023) Challenging the hemodynamic hypothesis in heart failure with preserved ejection fraction: is exercise capacity limited by elevated pulmonary capillary wedge pressure? Circulation 147:378–387CrossRefPubMed Sarma S, MacNamara JP, Balmain BN, Hearon CM Jr, Wakeham DJ, Tomlinson AR, Hynan LS, Babb TG, Levine BD (2023) Challenging the hemodynamic hypothesis in heart failure with preserved ejection fraction: is exercise capacity limited by elevated pulmonary capillary wedge pressure? Circulation 147:378–387CrossRefPubMed
14.
Zurück zum Zitat Wen S, Nguyen T, Gong M, Yuan X, Wang C, Jin J, Zhou L (2021) An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is). Diabetes Metab Syndr Obes 14:2955–2972CrossRefPubMedPubMedCentral Wen S, Nguyen T, Gong M, Yuan X, Wang C, Jin J, Zhou L (2021) An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is). Diabetes Metab Syndr Obes 14:2955–2972CrossRefPubMedPubMedCentral
Metadaten
Titel
Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction
verfasst von
Takuro Washio
Sarah L. Hissen
Ryosuke Takeda
John D. Akins
Denis J. Wakeham
Tiffany Brazile
Christopher M. Hearon Jr
James P. MacNamara
Satyam Sarma
Benjamin D. Levine
Paul J. Fadel
Qi Fu
Publikationsdatum
29.01.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 1/2024
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-023-01013-0

Weitere Artikel der Ausgabe 1/2024

Clinical Autonomic Research 1/2024 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.